Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NPHP3-ACAD11 readthrough is a noncoding RNA transcript produced by read-through transcription between the neighboring NPHP3 and ACAD11 genes on chromosome 3. It is classified as a candidate for nonsense-mediated mRNA decay and is therefore unlikely to encode a functional protein product[2][8]. As such, it does not function as a receptor, enzyme, transporter, or any other typical drug target class. No established therapeutic, biomarker, or diagnostic relevance is associated with this readthrough transcript[2][8][3]. The parent genes (NPHP3 and ACAD11) do have important biological and disease associations, but these do not apply directly to the NPHP3-ACAD11 readthrough transcript. The “readthrough” product should not be conflated with the individual protein products (nephrocystin-3 and ACAD11), which are distinct and do have characterized biological functions and disease relevance[1][7][10][9]. For therapeutically relevant information, refer to the individual genes NPHP3 or ACAD11, not the readthrough transcript.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NPHP3-ACAD11 readthrough (NPHP3-ACAD11).